Patents Assigned to Amgen
  • Glial cell line-derived neurotrophic factor
    Patent number: 6093802
    Abstract: A novel neurotrophic factor referred to as glial cell line-derived neurotrophic factor (GDNF) has been identified and isolated from serum free growth conditioned medium of B49 glioblastoma cells. Rat and human genes encoding GDNF have been cloned and sequenced. A gene encoding GDNF has been subcloned into a vector, and the vector has been used to transform a host cell in order to produce biologically active GDNF in a recombinant DNA process.
    Type: Grant
    Filed: May 26, 1995
    Date of Patent: July 25, 2000
    Assignee: Amgen Inc.
    Inventors: Leu-Fen H. Lin, Franklin D. Collins, Daniel H. Doherty, Jack Lile, Susan Bektesh
  • Human collagenase inhibitor sequence, recombinant vector system for using same and recombinant-DNA method for the manufacture of same
    Patent number: 6090585
    Abstract: A portable DNA sequence is disclosed which is capable of directing intracellular production of metalloproteinanse inhibitors. Vectors containing this portable DNA sequence are also set forth, including the vector pUC9-F5/237P10 (ATCC Accession No. 53003). A recombinant-DNA method for the microbial production of a metalloproteinase inhibitor, which method incorporates at least one of the portable DNA sequences and the vectors disclosed herein is described.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: July 18, 2000
    Assignee: Amgen Inc.
    Inventors: David F. Carmichael, David C. Anderson, George P. Stricklin, Howard G. Welgus
  • Efficient construction of gene targeting using phage-plasmid recombination
    Patent number: 6090629
    Abstract: A method for producing gene targeting constructs in bacterial by way of homologous recombination between bacterial phage and plasmids.
    Type: Grant
    Filed: October 31, 1997
    Date of Patent: July 18, 2000
    Assignee: Amgen, Inc.
    Inventor: Richard Woychik
  • Efficient construction of gene targeting vectors
    Patent number: 6090554
    Abstract: The present invention is directed to methods for producing or obtaining gene targeting constructs by way of homologous recombination in host cells and to targeting constructs produced by those methods. The invention is also directed to transgenic animals having targeted mutations introduced in to the cells of the animal using the targeting constructs of the invention.
    Type: Grant
    Filed: October 31, 1997
    Date of Patent: July 18, 2000
    Assignee: Amgen, Inc.
    Inventors: Richard Woychik, David Garfinkel
  • Eck receptor ligands
    Patent number: 6087167
    Abstract: Ligands which bind to the eck receptor are disclosed. More particularly, polypeptides which bind specifically to the eck receptor (eck receptor binding proteins or EBPs) and DNA sequences encoding said polypeptides are disclosed. Methods of treatment using eck receptor ligands and soluble eck receptor and disclosed, as are pharmaceutical compositions containing same. A rapid and sensitive method for the detection of receptor binding activity in crude samples is provided.
    Type: Grant
    Filed: October 28, 1997
    Date of Patent: July 11, 2000
    Assignee: Amgen Inc.
    Inventors: Timothy D. Bartley, William J. Boyle, Gary M. Fox, Andrew A. Welcher, Ella Magal, Richard A. Lindberg, Vann P. Parker
  • Mice lacking expression of osteoprotegerin
    Patent number: 6087555
    Abstract: Disclosed is a mouse in which expression of the gene encoding Osteoprotegerin is suppressed. Also disclosed is a nucleic acid construct useful in preparing such a mouse, and a cell line containing such construct.
    Type: Grant
    Filed: October 15, 1997
    Date of Patent: July 11, 2000
    Assignee: Amgen Inc.
    Inventors: Colin Dunstan, Scott Simonet, Ildiko Sarosi
  • Monoclonal antibody against utricular epithelium
    Patent number: 6080845
    Abstract: A non-naturally occurring peptide derived from EGF-like domains of NDF/heregulin protein isoforms is used to stimulate the proliferation of cells in the sensory epithelium of the inner ear. A monoclonal antibody against adult rat utricular epithelium is also described.
    Type: Grant
    Filed: January 28, 1999
    Date of Patent: June 27, 2000
    Assignee: Amgen Inc.
    Inventor: Josette F. Carnahan
  • Enhanced solubility of recombinant proteins
    Patent number: 6077689
    Abstract: Disclosed are methods for improving the solubility of a protein of interest produced recombinantly by expressing the protein of interest as a fusion protein with a member of the 14-3-3 family of proteins.
    Type: Grant
    Filed: December 24, 1997
    Date of Patent: June 20, 2000
    Assignee: Amgen Inc.
    Inventor: Marshall Davenport Snavely
  • Method for promoting cell proliferation and growth
    Patent number: 6075008
    Abstract: A method is disclosed which provides for the proliferation and growth of cells, such as prostate cells, by contacting them with an effective amount of a placental-derived prostate growth factor.
    Type: Grant
    Filed: November 12, 1998
    Date of Patent: June 13, 2000
    Assignee: Amgen Inc.
    Inventors: Catherine L. Farrell, Francis H. Martin, Rachel Yabkowitz
  • Ligands for EPH-like receptors
    Patent number: 6063903
    Abstract: Polypeptides which bind to one or more EPH-like receptors, particularly the HEK4 receptor, are described. The polypeptides are designated HEK4 binding proteins. Nucleic acids encoding HEK4 binding proteins, and expression vectors, host cells and processes for the production of the polypeptides are also described. The polypeptides are useful for modulating the growth and/or differentiation of a variety of tissues, including those from liver, kidney, lung, skin, digestive tract and nervous system and may be used to regenerate damaged or depleted tissue and to treat cancer or nervous system disorders.
    Type: Grant
    Filed: March 25, 1998
    Date of Patent: May 16, 2000
    Assignee: Amgen Inc.
    Inventors: Timothy D. Bartley, Gary M. Fox
  • Agouti-related proteins
    Patent number: 6060589
    Abstract: Disclosed is a novel gene termed ART which is expressed primarily in selected regions of the brain, as well as adrenal and lung tissues. Polypeptides encoded by ART are also disclosed, as are methods for preparing ART DNA and amino acid sequences.
    Type: Grant
    Filed: March 2, 1998
    Date of Patent: May 9, 2000
    Assignee: Amgen Inc.
    Inventors: Kevin Lee Stark, Roland Luethy
  • Nucleic acids encoding ligands for HEK4 receptors
    Patent number: 6057124
    Abstract: Polypeptides which bind to one or more EPH-like receptors, particularly the HEK4 receptor, are described. The polypeptides are designated HEK4 binding proteins. Nucleic acids encoding HEK4 binding proteins, and expression vectors, host cells and processes for the production of the polypeptides are also described. The polypeptides are useful for modulating the growth and/or differentiation of a variety of tissues, including those from liver, kidney, lung, skin, digestive tract and nervous system and may be used to regenerate damaged or depleted tissue and to treat cancer or nervous system disorders.
    Type: Grant
    Filed: January 27, 1995
    Date of Patent: May 2, 2000
    Assignee: Amgen Inc.
    Inventors: Timothy D. Bartley, Gary M. Fox
  • Nucleic acid molecules encoding the neurotrophic factor NNT-1
    Patent number: 6054294
    Abstract: Disclosed are nucleic acids encoding novel neurotrophic factors, designated NNT-1. Also disclosed are amino acid sequences for NNT-1 polypeptides, methods for preparing NNT-1 polypeptides, and other related aspects.
    Type: Grant
    Filed: December 12, 1997
    Date of Patent: April 25, 2000
    Assignee: Amgen Inc.
    Inventor: Ming-shi Chang
  • Method for preventing and treating hearing loss using a neuturin protein product
    Patent number: 6043221
    Abstract: The present invention relates generally to methods for preventing and/or treating injury or degeneration of cochlear hair cells and spiral ganglion neurons by administering a neurturin neurotrophic factor protein product. The invention relates more specifically to methods for treating sensorineural hearing loss.
    Type: Grant
    Filed: June 29, 1998
    Date of Patent: March 28, 2000
    Assignee: Amgen Inc.
    Inventors: Ella Magal, John M. Delaney
  • Method for reducing carryover contamination in an amplification procedure
    Patent number: 6037152
    Abstract: The present invention provides an efficient and economical method for reducing carryover contamination in an amplification procedure. The method of the present invention enables background caused by contaminant amplification product to be reduced or eliminated through the incorporation of at least one modification into the amplification product. The modified amplification product is readily distinguishable from the target sequence in a test sample. Prior to amplifying the target in a new test sample, the sample may be treated to selectively eliminate the contaminant amplification product so that it cannot be amplified in the new sample.
    Type: Grant
    Filed: January 23, 1995
    Date of Patent: March 14, 2000
    Assignee: Amgen Inc
    Inventors: Rodney M. Richards, Theodore Jones, Gregory S. Brown
  • Nucleic acids encoding myocardial peptides
    Patent number: 6034230
    Abstract: Disclosed are novel peptides that modulate inflammatory heart disease. Also disclosed are DNA molecules encoding the peptides, and methods of making the peptides.
    Type: Grant
    Filed: May 3, 1999
    Date of Patent: March 7, 2000
    Assignee: Amgen Canada Inc.
    Inventors: Kurt Bachmaier, Andrew John Hessel, Nickolaus Neu, Josef Martin Penninger
  • Diagnostic method for detection of placental-derived prostate growth factors
    Patent number: 6025204
    Abstract: A diagnostic method is described for the detection of placental-derived growth factors which involves contacting a biological tissue or fluid sample with a labeled antibody which is specific to the growth factors and detecting the labeled reaction product.
    Type: Grant
    Filed: November 12, 1998
    Date of Patent: February 15, 2000
    Assignee: Amgen Inc.
    Inventors: Catherine L. Farrell, Francis H. Martin, Rachel Yabkowitz
  • Substituted pyridine compounds and methods of use
    Patent number: 6022884
    Abstract: Selected novel substituted pyridine compounds are effective for prophylaxis and treatment of diseases, such as TNF-.alpha., IL-1.beta., IL-6 and/or IL-8 mediated diseases, and other maladies, such as pain and diabetes. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving inflammation, pain, diabetes, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    Type: Grant
    Filed: November 3, 1998
    Date of Patent: February 8, 2000
    Assignee: Amgen Inc.
    Inventors: Nathan B. Mantlo, Stephen T. Schlachter, John A. Josey
  • Formulations for non-viral in vivo transfection in the lungs
    Patent number: 6022737
    Abstract: Formulations useful in improving non-viral in vivo transfection of DNA in the lungs are provided. Formulations which comprise DNA with various additives are prepared and delivered to the lungs resulting in production of a transcription product.
    Type: Grant
    Filed: November 2, 1995
    Date of Patent: February 8, 2000
    Assignee: Amgen Inc.
    Inventors: Ralph Niven, Daniel J. Freeman
  • Stem cell factor formulations and methods
    Patent number: 6020469
    Abstract: Disclosed is a method of preparing a lyophilized stem cell factor (SCF). The method comprises mixing the SCF with histidine and/or glutamic acid and lyophilizing the formulation. Optionally, a bulking agent or an osmolarity regulating agent is included in the formulation prior to lyophilization.
    Type: Grant
    Filed: April 15, 1999
    Date of Patent: February 1, 2000
    Assignee: Amgen Inc.
    Inventor: Susan I. Hershenson